Alumis (ALMS) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed Alumis (ALMS) over the past year, gaining 1.9% versus a loss of 45.8%. Zevra Therapeutics is the larger company by market cap ($521.3 million vs $514.1 million), about 1.0 times the size. Zevra Therapeutics converts more of its revenue into profit, with a net margin of 78.2% versus -1011.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | ZVRA |
|---|---|---|
| Share price | $3.96 | $8.76 |
| Market cap | $514.09M | $521.26M |
| 1-day change | -8.55% | -3.42% |
| YTD return | -59.43% | -2.23% |
| 1-year return | -45.75% | +1.86% |
| 5-year return | — | +8.82% |
| P/E ratio (TTM) | — | 7.18 |
| Forward P/E | — | 9.84 |
| EPS (TTM) | $-3.53 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $24.05M | $106.47M |
| Revenue growth (YoY) | — | +350.91% |
| Net income (latest FY) | $-243.32M | $83.23M |
| Gross margin | — | 84.52% |
| Operating margin | -1886.92% | -59.12% |
| Net margin | -1011.75% | 78.17% |
| 52-week high | $31.35 | $15.04 |
| 52-week low | $3.94 | $8.01 |
| Distance from 52-week high | -87.37% | -41.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +540.91% | +162.56% |
| Average volume | 2.87M | 954.53K |
| Shares outstanding | 129.82M | 59.50M |
| Employees | 251 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed ALMS by 47.6 percentage points over the past year.
- Zevra Therapeutics is more profitable, keeping 78.2 cents of every revenue dollar as net income versus -1011.7 cents for Alumis.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 251 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
ALMS vs ZVRA FAQ
Which is bigger, Alumis or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $521.26M compared with $514.09M for Alumis (ALMS).
Which stock has performed better over the past year, ALMS or ZVRA?
ZVRA returned +1.86% over the past 12 months, compared with -45.75% for ALMS (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.